Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Weightless By Rocio Salas-Whalen, MDForeword by Mary Claire Haver, MD By Rocio Salas-Whalen, MDForeword by Mary Claire Haver, MD By Rocio Salas-Whalen, MDForeword by Mary Claire Haver, MDRead by Rocio Salas-Whalen, MD, Allyson Ryan and Graham Halstead NATIONAL BESTSELLER A board-certified physician shares her must-have guide to using GLP-1 medications, such as Ozempic, Wegovy, Mounjaro, and Zepbound, to reverse obesity and take charge of your health, with established strategies for maximizing your results This book is a game-changer
JH: Writing review and editing, Methodology
Randomization: CagriSema 2.4 mg/2.4 mg vs Semaglutide 2.4 mg vs placebo
Gastrointestinal adverse events during follow-up were statistically significant ( Oral semaglutide has been studied in PIONEER 6 (designed as a non-inferiority trials), with a mean follow-up of 1.3 years and positive results for the primary endpoint: the MACE rate was reduced by 21% but did not achieve statistically significant differences
